National Association of Testing Authorities, Australia
Scope of Accreditation
Incite Genomics Pty Ltd
Scope of Accreditation
Incite Genomics
ISO 15189 (2012)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Service | Product | Determinant |
---|---|---|
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Buccal swabs | ABC transporters; Bilirubin-UGT enzyme; Catechol-O-methyltransferase (COMT) pharmacogenomic studies; Cytochrome P450 pharmacogenomic studies; Dihydropyrimidine dehydrogenase (DPYD) genotyping; HLA-B27; Human carboxylesterase 1 (CES1) pharmacogenomic studies; Nudix hydrolase 15 gene (NUDT15); OPRM1 pharmacogenomic studies; SCL01B1 pharmacogenomic studies; Thiopurine methyltransferase (TPMT) genotyping; VKORC1 pharmacogenomic studies; α1-Antitrypsin |
Molecular genetics - DNA extraction | Buccal swabs | Viable DNA |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
20374
Site No.
24392
Print date
28 Nov 2024
END OF SCOPE